Related Experiment Video
Updated: Jun 15, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
[Obesity and liver disease]
María Eugenia Miquilena Colina1, Carmelo García Monzón
1Unidad de Investigación, Hospital Universitario Santa Cristina, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, España.
Obesity increases the risk of non-alcoholic fatty liver disease (NAFLD) and worsens chronic liver conditions like hepatitis C. Chronic inflammation from fat tissue links metabolic issues, fat buildup, and liver inflammation, highlighting fat
Area of Science:
- Hepatology and Metabolic Syndrome
Background:
- Obesity is a significant risk factor for non-alcoholic fatty liver disease (NAFLD).
- Adipose tissue inflammation and adipokine secretion link metabolic dysfunction to liver inflammation.
- Obesity and insulin resistance may accelerate the progression of various chronic liver diseases, including hepatitis C virus (HCV) infection.
Purpose of the Study:
- To explore the connection between obesity, metabolic alterations, and liver disease progression.
- To highlight the role of hepatocellular lipotoxicity in NAFLD pathogenesis.
- To examine the influence of obesity-related factors on HCV-mediated liver disease.
Main Methods:
- Review of current literature on obesity, NAFLD, and chronic liver diseases.
- Analysis of the role of adipose tissue inflammation and adipokines.
- Investigation of the impact of insulin resistance on liver disease progression.
Main Results:
- Obesity is strongly associated with increased NAFLD risk.
- Chronic inflammation in adipose tissue contributes to liver inflammation and lipotoxicity.
- Obesity and insulin resistance appear to exacerbate HCV-related liver disease and other chronic liver conditions.
Conclusions:
- Obesity plays a crucial role in the development and progression of NAFLD.
- Hepatocellular lipotoxicity, driven by metabolic alterations linked to obesity, is central to NAFLD pathogenesis.
- Managing obesity and associated metabolic issues is vital for mitigating the progression of diverse chronic liver diseases.
More Related Videos
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:46Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Drug Dosing: Obese Patients